Results 191 to 200 of about 506,903 (380)

Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment Studies

Clinical Pharmacology &Therapeutics, EarlyView.
The US Food and Drug Administration 2024 guidance prefers regression analysis over categorical analysis for pharmacokinetic data for studies that assess pharmacokinetics in patients with impaired renal functions. The objective of this study was to compare these two statistical methods for pharmacokinetic data analysis of renal impairment studies ...
Gerald Chun‐To So, Ying Grace Li, Stephen D. Hall, Jenny Chien, Christopher D. Payne, Maria M. Posada, Maria Lucia Buziqui Piruzeli, Yan Jin   +7 more
wiley   +1 more source

Advancing Predictions of Oral Drug Absorption, CYP3A4 Induction, and Transporter‐Mediated Interactions Using a Human Primary Intestinal 3D Model (EpiIntestinal™)

Clinical Pharmacology &Therapeutics, EarlyView.
Accurate prediction of oral drug absorption in humans is essential for early drug development; however, physiologically relevant human models are lacking. This study aims to comprehensively assess the EpiIntestinal™, a human primary intestinal 3D model, for its ability to predict oral absorption (Fa), intestinal availability (Fg), CYP3A4 induction, and
Paresh P. Chothe, Andrea Whitcher‐Johnstone, Aniruddha Karve, Diane Ramsden, Niresh Hariparsad   +4 more
wiley   +1 more source

Identification and characterization of an NADPH-cytochrome P450 reductase derived peptide involved in binding to cytochrome P450

, 1991
Steven G. Nadler, Henry W. Strobel
openalex   +1 more source

Cytochrome P450 diversity in the tree of life.

Biochimica et Biophysica Acta - Proteins and Proteomics, 2018
D. Nelson
semanticscholar   +1 more source

Cytochrome P450 2D6 *17 and *29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2D6 alleles with low frequency in Eurocentrically biased study populations are often excluded from pharmacogenetic investigation and consequently may have misassigned activity values. This health inequity may be contributing to imprecise dose predictions for CYP2D6‐metabolizing drugs.
Oyinlade Kehinde, Samuel E. Vaughn, Ogochukwu Amaeze, Paul Toren, Brandon Retke, Akinyemi Oni‐Orisan, Laura B. Ramsey   +6 more
wiley   +1 more source

Effects of palm carotenoids in rat hepatic cytochrome P450-mediated benzo(a)pyrene metabolism

, 1991
Barrie Tan, F C H Chu
openalex   +1 more source

Cytochrom P450 [PDF]

, 2017
O. A. Gressner, A. M. Gressner
openaire   +1 more source

Interpretation of in vitro concentration‐response data for risk assessment and regulatory decision‐making: Report from the 2022 IWGT quantitative analysis expert working group meeting

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Quantitative risk assessments of chemicals are routinely performed using in vivo data from rodents; however, there is growing recognition that non‐animal approaches can be human‐relevant alternatives. There is an urgent need to build confidence in non‐animal alternatives given the international support to reduce the use of animals in toxicity ...
Marc A. Beal, Guangchao Chen, Kerry L. Dearfield, Min Gi, Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Alexandra S. Long, David P. Lovell, Barbara L. Parsons, Stefan Pfuhler, John Wills, Andreas Zeller, George Johnson, Paul A. White   +14 more
wiley   +1 more source

Spectroscopic characterization of a newly isolated cytochrome P450 from Rhodococcus rhodochrous

, 1993
Lucia Banci, Ivano Bertini, Lindsay D. Eltis, Roberta Pierattelli   +3 more
openalex   +1 more source

Midazolam is metabolized by at least three different cytochrome P450 enzymes

, 1994
Christoph Wandel, R. Böcker, H. Böhrer, Amanda Browne, E. Rügheimer, Encily R. Martin   +5 more
openalex   +1 more source